Waldencast Stock News

Waldencast plc. (NASDAQ:WALD ) Q3 2024 Earnings Conference Call November 21, 2024 8:30 AM ET Company Participants Allison Malkin - Investor Relations, ICR Michel Brousset - Founder and Chief Executive Officer Manuel Manfredi - Chief Financial Officer Conference Call Participants Jonna Kim - TD Cowen Dana Telsey - Telsey Advisory Group Sydney Wagner - Jefferies Susan Anderson - Canaccord Genuity...

$70.2 million of Net Revenue Q3 2024+34.6% Comparable Net Revenue GrowthBoth brands accelerating from Q2 2024+45.5% Obagi Medical and +23.5% Milk Makeup vs Q3 2023Adjusted EBITDA of $11.4 million, up +134.0% vs Q3 2023

LONDON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Waldencast plc, (NASDAQ: WALD) (“Waldencast”), a global multi-brand beauty and wellness platform provided the details for its Third Quarter Fiscal 2024 conference call and webcast. As previously announced, the Company will issue its Third Quarter Fiscal 2024 results on November 20, 2024 after the close of the U.S. market.

NEW YORK, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), a global multi-brand beauty and wellness platform, announced today that Hind Sebti, Kelly Brookie and Roberto Thompson have been appointed to its board of Directors (the “Board”), effective September 26, 2024. These executives bring extensive professional experience further enhancing the b...

These New Products are the Latest Innovation to Obagi's ELASTIDERM® Collection These New Products are the Latest Innovation to Obagi's ELASTIDERM® Collection

Waldencast plc. (NASDAQ:WALD ) Q2 2024 Earnings Conference Call August 28, 2024 8:30 AM ET Company Participants Allison Malkin - Investor Relations, ICR Michel Brousset - Founder & Chief Executive Officer Manuel Manfredi - Chief Financial Officer Conference Call Participants Olivia Tong - Raymond James Linda Bolton Weiser - DA Davidson Dana Telsey - Telsey Advisory Group Operator Greetings.

Waldencast posted Q2 sales that came in far above the market's expectations. Comparable sales growth accelerated significantly on a sequential quarterly basis.

$63.3 million of Net Revenue Q2 2024 +25.7% net revenue Comparable Growth: +30.9% Obagi Medical and +20.0% Milk Makeup vs Q2 2023 Adjusted EBITDA of $6.3 million, up +64.5% vs Q2 2023